By John Vandermosten, CFA
NASDAQ:LEXX
READ THE FULL LEXX RESEARCH REPORT
We update investors on Lexaria Bioscience Corporation’s (NASDAQ:LEXX) latest news on the occasion of the company’s report of fiscal year 2026 first quarter financial results for the period ending November 30th, 2025. During the first quarter, the company executed a capital raise, achieved several milestones for its GLP-1 agonist studies, and extended its Material Transfer Agreement with an undisclosed pharmaceutical company. Following the quarter end, Lexaria presented its Phase Ib results for study GLP-1-H24-4, emphasizing the material reduction in side effects for DehydraTECH (DHT)-formulated semaglutide.
Since our previous report in late December, Lexaria has released an annual letter from the CEO, been awarded additional patents, and reported final results from human pilot study #5 (GLP-1-H25-5). CEO Richard Christopher summarized the key achievements and objectives for Lexaria in his letter, centering on the performance of the DHT-formulated GLP-1 agonists that have been evaluated in many preclinical and clinical studies over the last several years. The most important takeaways from this work have been the reduction in adverse events compared with the injected version of the diabetes and weight loss drugs, as well as confirming the products’ ability to improve glucose, insulin, and weight using the DHT formulation. Supporting these efforts is a portfolio of 60 DHT patents granted around the world, with the most recent wave emphasizing the delivery platform’s treatment of nicotine, hypertension, epilepsy, and diabetes.
Fiscal Year 2026 First Quarter Results
Lexaria reported fiscal year 2026 first quarter results for the three-month period ending November 30th, 2025, through the filing of its Form 10-Q. The company reported no revenues and total operating expense of $1.6 million, resulting in net loss of ($1.6) million or ($0.07) per diluted common share.
For the quarter and versus the comparable prior year period:
- Revenue totaled $0 compared to $184,000 as the Premier arrangement expired at the end of the last fiscal year, and no B2B product revenues were recognized compared with revenues of $174,000 and $9,923;
- Research and development expenses totaled $671,000, down 66% from $2.0 million, reflecting the completion of GLP-1 agonist trials, including the Phase Ib GLP-1-H24-4 study;
- General and administrative expenses totaled $902,000, down 2% from $919,000 on account of reduced spending on advertising and promotions and lower consulting fees, partially offset by higher consulting fees and salaries, and greater legal and professional fees;
- Other loss of ($22,000) represented unrealized loss on marketable securities related to decreases in fair value and a small contribution from interest income;
- Net loss was ($1.6) million, or ($0.07) per share, compared to net loss of ($2.7) million or ($0.16) per share.
As of November 30th, 2025, cash and marketable securities totaled $4.4 million, which compares to $1.8 million at the end of fiscal year 2025. Cash burn for 1Q:26 was approximately ($989,000). Cash from financing over the same period totaled $3.5 million from equity sales. Following the end of the quarter, Lexaria executed additional equity sales, raising a net $3.0 million.
CEO Letter to Stakeholders
CEO Richard Christopher celebrates his first full calendar year as Lexaria’s Chief Executive Officer and communicates the company’s 2025 achievements and future expectations in his annual letter. In 2025, Lexaria generated results for its #3, #4, #5, and biodistribution studies. Study #4 was a Phase Ib registrational study conducted in Australia, which we summarize later in this report, and study #5 examined DehydraTECH (DHT) liraglutide and is also reviewed. 10 additional patents were issued in 2025, and the company’s MTA was extended. 2025’s focus was almost exclusively upon evaluating the DHT technology with the three leading GLP-1 agonist drugs in the market: semaglutide, tirzepatide, and liraglutide.
Mr. Christopher sets the stage in the weight loss space, citing 2025 growth for the GLP-1 agonist class of 51% in contrast to the performance of Rybelsus of just 2%. The company believes that it can make an impact on the growth of oral administration of these products with its technology that can limit gastrointestinal side effects. Lexaria is also advancing in other areas with its DHT technology, including cardiovascular disease, sleep apnea, metabolic dysfunction associated steatohepatitis (MASH/NASH), chronic kidney disease, and neurodegenerative diseases.
New Patents
The January 12th CEO letter publicized the issuance of 10 patents in 2025, bringing the company’s total to 56. Ten days later, on January 22nd, Lexaria announced the award of six additional patents since early October 2025 that span geographies from the US and Canada to Japan and Australia. These awards are in the following families:
- Compositions and Methods for Sublingual Delivery of Nicotine
- First patent in Australia granted
- Compositions and Methods for Treating Hypertension
- First European Union patent granted
- Compositions and Methods for Treating Epilepsy
- Two new Australian patents granted
- One new European Union patent granted
- Compositions and Methods for Treating Diabetes
Summary
Lexaria reports its fiscal year first quarter 2026 results along with final results for the Human Pilot Study #5. CEO Christopher updates investors on his patent portfolio and communicates the next steps for the GLP-1 agonist program. We expect the team will increase its business development activity, leveraging its October arrangement with an advisory firm. We believe that the many biosimilar manufacturers of liraglutide will provide a fertile market eager to meet the demand for an oral formulation of the biologic for weight loss. The improved side effect profile for DHT-formulated GLP-1 agonists is a welcome feature that addresses one of the primary shortcomings of the existing offerings. We note that there are at least six biosimilar producers of liraglutide, each of which could be a prospective partner for Lexaria.[1]
Post fiscal year end, Lexaria raised an additional $7.5 million gross that should fund the company for 2026. Now that Lexaria has additional data to share, we expect final disposition for the MTA and further conversations with partners that may lead to collaborations. DehydraTECH offers improved speed of onset, better bioavailability, reduced adverse events, and potentially a favorable regulatory pathway via the 505(b)(2) regulatory pathway. The reduced level of adverse events, especially GI tolerability, as shown in all of Lexaria’s human studies, is a particularly attractive feature.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
________________________
[1] We identified liraglutide biosimilars manufactured by Lupin, Meitheal Pharmaceuticals, Teva, Sandoz and others including those from compound pharmacies.